146 related articles for article (PubMed ID: 15286635)
1. Fast track to MS drug.
Sheridan C
Nat Biotechnol; 2004 Aug; 22(8):939-41. PubMed ID: 15286635
[No Abstract] [Full Text] [Related]
2. A new approach for MS.
Morrow T
Manag Care; 2005 Jan; 14(1):85-7. PubMed ID: 15742758
[No Abstract] [Full Text] [Related]
3. MS drug back on market under restricted program.
FDA Consum; 2006; 40(4):7. PubMed ID: 17243280
[No Abstract] [Full Text] [Related]
4. Tricky FDA debate: should a risky drug be approved again?
Mathews AW; Westphal SP
Wall St J (East Ed); 2006 Feb; ():B1, B4. PubMed ID: 16528879
[No Abstract] [Full Text] [Related]
5. Lymphoma treatment approved.
AIDS Patient Care STDS; 1998 Mar; 12(3):231. PubMed ID: 11361944
[No Abstract] [Full Text] [Related]
6. Tysabri back on market.
Sheridan C
Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
[No Abstract] [Full Text] [Related]
7. Expanded clinical trials of treatments for multiple sclerosis: copolymer 1 (COP-1) treatment investigational new drug (IND) program.
Stark Y
Ann Neurol; 1994 Jul; 36(1):114-5. PubMed ID: 8024251
[No Abstract] [Full Text] [Related]
8. Natalizumab (Tysabri) returns.
Med Lett Drugs Ther; 2006 Sep; 48(1243):76. PubMed ID: 16977289
[No Abstract] [Full Text] [Related]
9. Off-label uses of monoclonal antibodies for treatment of B-cell lymphoid or myeloid malignancies.
Tecnologica MAP Suppl; 2001 Jul; ():14-7. PubMed ID: 11718149
[No Abstract] [Full Text] [Related]
10. Fast track for antiretroviral.
AIDS Patient Care STDS; 2003 Dec; 17(12):665. PubMed ID: 14750222
[No Abstract] [Full Text] [Related]
11. How Tysabri survived.
Huggett B
Nat Biotechnol; 2009 Nov; 27(11):986. PubMed ID: 19898447
[TBL] [Abstract][Full Text] [Related]
12. FDA. Once on 'fast track,' avastin now derailed.
Couzin-Frankel J; Ogale Y
Science; 2011 Jul; 333(6039):143-4. PubMed ID: 21737712
[No Abstract] [Full Text] [Related]
13. US drug approval ignores science's subtleties, experts say.
Waltz E
Nat Med; 2006 Apr; 12(4):373. PubMed ID: 16598269
[No Abstract] [Full Text] [Related]
14. Monoclonal antibody successes in the clinic.
Reichert JM; Rosensweig CJ; Faden LB; Dewitz MC
Nat Biotechnol; 2005 Sep; 23(9):1073-8. PubMed ID: 16151394
[TBL] [Abstract][Full Text] [Related]
15. Expanded clinical trials of treatments for multiple sclerosis. The Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis of The National Multiple Sclerosis Society.
Whitaker JN
Ann Neurol; 1993 Dec; 34(6):755-6. PubMed ID: 8250523
[No Abstract] [Full Text] [Related]
16. Targeted therapy trials: approval strategies, target validation, or helping patients?
Hoff PM; Ellis LM
J Clin Oncol; 2007 May; 25(13):1639-41. PubMed ID: 17470854
[No Abstract] [Full Text] [Related]
17. Berlex continues legal challenge to FDA over MS drug.
Glaser V
Nat Biotechnol; 1996 Jul; 14(7):811-2. PubMed ID: 9630997
[No Abstract] [Full Text] [Related]
18. Biogen, Serono squabble over MS market.
Davidson S
Nat Biotechnol; 2001 Aug; 19(8):696-7. PubMed ID: 11479543
[No Abstract] [Full Text] [Related]
19. New treatment for multiple sclerosis.
FDA Consum; 2005; 39(1):6-7. PubMed ID: 15818796
[No Abstract] [Full Text] [Related]
20. Cleanup crew.
Leslie M
Science; 2015 Mar; 347(6226):1058-9, 1061. PubMed ID: 25745143
[No Abstract] [Full Text] [Related]
[Next] [New Search]
